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Ovarian carcinomas with mutations in the tumour suppressor BRCA2 are particularly sensitive to platinum compounds 1 . However, such carcinomas ultimately develop cisplatin resistance. The mechanism of that resistance is largely unknown 2 . Here we show that acquired resistance to cisplatin can be mediated by secondary intragenic mutations in BRCA2 that restore the wildtype BRCA2 reading frame. First, in a cisplatin-resistant BRCA2-mutated breast-cancer cell line, HCC1428, a secondary genetic change in BRCA2 rescued BRCA2 function. Second, cisplatin selection of a BRCA2-mutated pancreatic cancer cell line, Capan-1 (refs 3, 4), led to five different secondary mutations that restored the wild-type BRCA2 reading frame. All clones with secondary mutations were resistant both to cisplatin and to a poly(ADP-ribose) polymerase (PARP) inhibitor (AG14361). Finally, we evaluated recurrent cancers from patients whose primary BRCA2-mutated ovarian carcinomas were treated with cisplatin. The recurrent tumour that acquired cisplatin resistance had undergone reversion of its BRCA2 mutation. Our results suggest that secondary mutations that restore the wild-type BRCA2 reading frame may be a major clinical mediator of acquired resistance to platinum-based chemotherapy.
Women with ovarian cancer generally have a high initial response to platinum-based chemotherapy, but over time most ovarian carcinomas become refractory, and most patients die with progressive chemoresistant disease 2 . The molecular basis of initial platinum sensitivity and acquired resistance remains largely unknown. Individuals with germline mutations in BRCA1 or BRCA2 (BRCA1/2) have an increased risk of developing cancer in the breast and ovary 5 as well as in some other organs including the pancreas and prostate 6 . BRCA2 is identical to the Fanconi anaemia gene FANCD1 7 . The BRCA2 protein directly binds to and regulates RAD51, an essential protein for DNA repair through homologous recombination 8 . Tumours from BRCA1/ 2 mutation carriers usually have deletion of the wild-type allele at the BRCA1/2 locus and are BRCA1/2-deficient [9] [10] [11] . BRCA1/2-deficient cancer cells are hypersensitive to DNA-crosslinking agents including cisplatin 1, 12 . Therefore, cisplatin or its derivative, carboplatin, is a logical choice for the treatment of BRCA1/2-mutated tumours 13 , and women with BRCA1/2-mutated ovarian carcinoma have a better prognosis than those without BRCA1/2 mutation if they receive platinum-based therapy 14, 15 . However, even BRCA1/2-mutated tumours eventually develop platinum resistance.
In several genetic disorders such as Fanconi anaemia, spontaneous genetic alterations compensating for inherited disease-causing mutations have been described 16 . These alterations in Fanconi anaemia include secondary genetic changes of one of the mutated Fanconi anaemia alleles, such as back-mutations to wild type, compensatory mutations in cis, intragenic crossovers and gene conversion [16] [17] [18] . We speculated that secondary mutations in BRCA2-mutated alleles might also occur in cancer cells during chemotherapy.
To study the mechanism of acquired cisplatin resistance of BRCA2-mutated cancer, first we screened 12 human breast-cancer cell lines for alterations in BRCA2 protein expression (Fig. 1a) . A pancreatic cancer cell line, Capan-1 (refs 3, 4) , with a truncated BRCA2 protein, was used as a control.
From breast-cancer cell line HCC1428 19 , BRCA2 protein was undetectable by western blotting using anti-BRCA2 (Ab-1), which recognizes the middle part of BRCA2 (Fig. 1a) ; however, it was detectable with anti-BRCA2 (Ab-2), which recognizes the BRCA2 C terminus. The small size of HCC1428 BRCA2 identified by Ab-2 suggested that the protein might have an internal in-frame deletion. Constitutional DNA from a lymphoblast cell line (HCC1428BL) from the same patient had one wild-type BRCA2 allele and one mutant allele with a frameshift mutation, 6174delT, which is common in the Ashkenazi Jewish population (Fig. 1b and Supplementary  Fig. 1 ) 20 . Sequence of genomic DNA from HCC1428 cancer cells revealed no wild-type allele and a mutant allele with a 2,135-base-pair (bp) deletion surrounding the original 6174delT mutation and the exon 11/ intron 11 junction (Fig. 1c and Supplementary Fig. 1 ). Sequence of complementary DNA (cDNA) indicated that this deletion activated two cryptic splice donor sites in exon 11, resulting in expression of two transcripts with in-frame deletions ( Fig. 1d and Supplementary  Fig. 1 ). HCC1428 transcript 1 had a 2,640-bp deletion and encoded a protein lacking amino acids 1401-2281. Transcript 2 had a 2,187-bp deletion and encoded a protein lacking amino acids 1552-2281 (Fig. 1d, e and Supplementary Fig. 1 ). Both HCC1428 BRCA2 proteins retain the single-strand DNA (ssDNA)-binding domain and the carboxy (C)-terminus nuclear localization signals (NLSs), whereas these domains are lost in BRCA2.6174delT (Fig. 1e) . A recent report that only one BRC repeat plus ssDNA-binding domain and NLSs are sufficient for BRCA2 function 21 suggests that the novel BRCA2 proteins in HCC1428 might be functional. Indeed, HCC1428 cells were resistant to cisplatin (Fig. 1g) . Furthermore, depletion of these novel BRCA2 proteins with short interfering RNA (siRNA) restored sensitivity of HCC1428 cells to cisplatin (Fig. 1f, g ).
HCC1428 was derived after chemotherapy from the pleural effusion of a 49-year-old woman with stage IV breast carcinoma who died six months later 19 . We speculate that the patient's chemotherapy selected in vivo for secondary mutations in BRCA2-mutated breast tumour cells.
To test this hypothesis, we selected in vitro for cisplatin-resistant clones from the cisplatin-sensitive BRCA2-mutated pancreatic cancer cell line Capan-1. Capan-1 has the mutant allele BRCA2.6174delT, but no wild-type allele ( Supplementary Fig.  5a ) 3, 4 . Fluorescence in situ hybridization (FISH) revealed that Capan-1 harbours at least two copies of the BRCA2 gene, indicating duplication of the chromosome 13 with the mutant BRCA2 gene ( Supplementary Fig. 2 ).
After selection in cisplatin, we obtained 14 cisplatin-resistant Capan-1 clones from twelve million cells ( Supplementary Fig. 3 and Supplementary Table 1) . Importantly, in 7 of these 14 clones, BRCA2 expression, at close to the length of the wild-type protein, was now detectable (Fig. 2) . The other seven cisplatin-resistant clones still lacked BRCA2 protein expression.
In all seven cisplatin-resistant clones with restored, nearly fulllength BRCA2 protein expression, we identified additional BRCA2 mutations that corrected the frameshift caused by the 6174delT mutation (Fig. 2b, Supplementary Figs 4 and 5, and Supplementary Table 1 ). These secondary genetic changes included a small deletion, insertion and deletion/insertion at sites close to the original mutation, and in-frame deletions surrounding the original mutation site. Interestingly, in each clone we observed both the original mutant BRCA2.6174delT sequence and the 6174delT sequence with additional mutations (Supplementary Figs 4 and 5), indicating that the secondary mutations occurred on only one of the duplicated mutant BRCA2 copies ( Supplementary Fig. 5g ). None of the seven cisplatinresistant clones lacking BRCA2 protein expression harboured additional mutations in BRCA2.
Next, we assessed the function of the restored BRCA2 proteins in the 14 cisplatin-resistant Capan-1 clones by evaluating RAD51 foci ssDNA-binding domain HCC1428 genomic DNA
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Exon 11 Exon 12 4882 7070 formation after exposure to ionizing radiation (Fig. 3a) . Ionizingradiation-induced RAD51 foci formation was impaired in parental Capan-1 (ref. 1). In contrast, in six of the seven cisplatin-resistant Capan-1 clones with restored BRCA2 expression, ionizing-radiationinduced RAD51 foci formation was significantly improved, suggesting that these novel BRCA2 isoforms are functional.
In most of the cisplatin-resistant Capan-1 clones without secondary mutations, ionizing-radiation-induced RAD51 foci formation remained impaired (Fig. 3a) , suggesting that these clones acquired cisplatin resistance through mechanisms other than the restoration of the BRCA2-RAD51 pathway.
Next, we analysed the homologous-recombination-based DNA double-strand-break (DSB) repair function of some of the novel BRCA2 proteins by using an I-SceI-dependent DR-GFP reporter assay in BRCA2-deficient V-C8 Chinese hamster cells 22 . The proportions of GFP-positive cells arising through the repair of I-SceI-induced DSB by homologous recombination after transfection of various mutant BRCA2 constructs were compared (Fig. 3b,  Supplementary Fig. 6 and Supplementary Table 2 
These results indicate that the novel BRCA2 proteins efficiently promote homologous recombination.
PARP inhibitors selectively kill BRCA1/2-deficient tumour cells 23, 24 and are expected to become a therapeutic option for patients with BRCA1/2-mutated cancers 13 . However, it remains unclear whether BRCA1/2-mutated tumours with acquired cisplatin resistance are sensitive to PARP inhibitors. We tested the sensitivity of cisplatin-resistant Capan-1 clones to a PARP inhibitor (AG14361) (Fig. 3c) . Both parental Capan-1 and cisplatin-resistant clones without secondary mutations were sensitive to the PARP inhibitor. In contrast, Capan-1 clones with secondary BRCA2 mutations were resistant, consistent with the restoration of functional BRCA2 in these clones, although the differences in the sensitivity between parental Capan-1 and these clones were relatively small.
Finally, we analysed tissues of five patients with BRCA2 mutations and recurrent ovarian carcinomas previously treated with platinum. Three recurrent tumours were clinically refractory to platinum and two were sensitive (Supplementary Table 3 ). Platinum-refractory tumour UW3548 revealed genetic reversion of BRCA2.6174delT (Fig. 4) . Evidence for genetic reversion is as follows. Constitutional DNA of this patient was heterozygous for BRCA2.6174delT and at two single nucleotide polymorphisms (SNPs). As expected, the microdissected specimen of the recurrent tumour was hemizygous at each SNP, reflecting loss of heterozygosity of BRCA2 in the tumour. However, in the same tumour sample, sequences of both BRCA2.6174delT and wild-type BRCA2 were detected, suggesting that the recurrent tumour had acquired wild-type BRCA2 by genetic reversion, or back mutation to wild type. We speculate that the appearance of both mutant and wild-type sequences resulted from duplication of the mutant BRCA2 followed by genetic reversion of one of the duplicates, similar to the situation occurring in Capan-1 clones with secondary mutations (Supplementary Figs 4 and 5) . A larger clinical study is warranted to determine the prevalence and clinical significance of in vivo secondary mutations in BRCA2 in human tumours.
The second platinum-refractory relapsed tumour (CS2) presented a complex profile. This patient carried germline mutations in both BRCA1 and BRCA2 (Supplementary Fig. 7 ). The primary ovarian tumour was sensitive to platinum and showed loss of the wild-type BRCA1 allele and heterozygosity of BRCA2, indicating that carcinogenesis was primarily driven by the BRCA1 mutation. Importantly, the recurrent platinum-refractory tumour had lost the mutant BRCA2 allele. We speculate that loss of the mutant BRCA2 allele was the result of selection by chemotherapy and contributed to platinum resistance.
The tumour of a third patient (UW174) recurred five months after her primary chemotherapy, so her tumour is defined as clinically refractory to platinum. No secondary mutation in BRCA2 was detectable in the tumour specimen of this patient. Recurrent tumours of two other patients (CS9 and CS15) were sensitive to cisplatin. No secondary genetic alterations in BRCA2 were identified in either of these tumours.
Taken together, our data demonstrate that secondary mutations that correct the frameshift caused by mutated BRCA2 alleles are a mechanism of acquired resistance to cisplatin ( Supplementary  Fig. 8 ). Testing for secondary mutations in platinum-treated BRCA2-mutated cancers may be clinically important, because tumours with secondary mutations are likely to be resistant both to cisplatin and PARP inhibitors. Theoretically, it might be possible to re-sensitize these tumours to cisplatin and to PARP inhibitors by treatment with drugs such as proteasome inhibitors that inhibit RAD51 recruitment to sites of DNA repair 25 . In contrast, platinum-resistant BRCA2-mutated tumours without secondary BRCA2 mutations may remain sensitive to PARP inhibitors. Supplementary Fig. 9 .) a, Seven Capan-1 clones indicated with a single asterisk restored apparently full-length BRCA2 protein expression. Cell lysates from indicated cells were immunoblotted with BRCA2 antibodies (Ab-1 and Ab-2). A double asterisk indicates a band presumed to be non-specific. b, Schematic presentation of BRCA2 proteins encoded by transcripts in Capan-1 clones. In all of the BRCA2-restored Capan-1 clones, additional genetic changes in exon 11 of BRCA2 were detected (Supplementary Table 1 , and Supplementary Figs 4 and 5) . All of these secondary genetic changes (shown as white arrowheads or black horizontal bars) cancel the frameshift caused by the original mutation (6174delT, black arrowheads), and the encoded BRCA2 proteins have intact C-terminal regions containing an ssDNA-binding domain and NLSs.
Treatment with cisplatin could facilitate secondary mutations by increasing the mutation rate through DNA damaging effects. Alternatively, because BRCA2 is involved in error-free DNA repair, homologous recombination, it is possible that BRCA2 deficiency itself promotes secondary mutations through compensatory use of more error-prone DNA repair processes 26 . Secondary mutations are relevant as a mechanism of resistance only in those tumours that contain frameshift mutations in BRCA2, which occurs in only 5% of ovarian carcinomas. However, BRCA2 mRNA expression is undetectable in 13% of ovarian carcinoma 27 . We speculate that other mechanisms yet to be identified could restore BRCA2 in acquired cisplatin resistance in these sporadic cases.
Our findings may be applicable to cancers other than ovarian. Secondary mutations in BRCA2 occurred in a mitomycin-C-resistant human acute myeloid leukaemia cell line with bi-allelic BRCA2 mutations derived from a patient with Fanconi anaemia (D1 subtype) 28 and BRCA2-mutated Chinese hamster fibroblast lines 29 , suggesting that secondary mutations in BRCA2 may have a general role in resistance to DNA-crosslinking agents in cells derived from various organs.
Secondary mutation of mutated BRCA2 is reminiscent of mechanisms of acquired resistance of Philadelphia-chromosome-positive leukaemia to imatinib 30 , such as BCR-ABL point mutations that prevent imatinib binding. In both cases, the disease-causing mutations increase tumour sensitivity to specific agents, but development , n 5 3) . c, BRCA2-restored Capan-1 clones are resistant to a PARP inhibitor. Capan-1, its clones with secondary BRCA2 mutation (C2-6, C2-12 and C2-14) and clones without secondary BRCA2 mutation (C2-10, C2-11 and C2-13) were treated with a PARP inhibitor (AG14361) at the indicated concentrations for six days, and survival fraction was measured by XTT assay (mean 6 s.e.m., n 5 6). locus (IVS21-66C/T and IVS25-299C/G) were detected, in addition to a heterozygous mutation (6174delT). In the microdissected recurrent tumour specimen, loss of heterozygosity of the SNPs was confirmed, but mixed sequences of 6174delT and wild-type BRCA2 were detected.
of further mutations in the disease-causing genes during targeted drug treatment leads to drug resistance. It will be important to explore mechanisms for restoring drug sensitivity.
METHODS SUMMARY
HCC1428, Capan-1 and a lymphoblast cell line (HCC1428BL) were purchased from the American Type Culture Collections. Cisplatin-resistant Capan-1 clones were generated by long-term culture in cisplatin (2 mM)-containing medium. Polymerase chain reaction (PCR)-amplified BRCA2 gene fragments were analysed for sequence alterations with BigDye Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems). All nucleotide numbers refer to the wild-type cDNA human sequence of BRCA2 (accession number U43746; version U43746.1 GI: 1161383) and BRCA1 (U14680.1).
For western blot analysis, anti-BRCA2 Ab-1 (1:100; OP95, EMD Biosciences), anti-BRCA2 Ab-2 (1:100; PC146, EMD Biosciences), and anti-FANCA (1:1000, (#7488) (a gift from M. Hoatlin)) were used. For immunofluorescence microscopy, cells were fixed with 4% paraformaldehyde in PBS for 10 min, followed by permeabilization with 0.25% Triton X-100 in PBS (10 min). A primary antibody (anti-RAD51 (Ab-1) (1:1000, PC130, EMD Biosciences)) and a secondary antibody (Alexa Fluor 488 goat anti-rabbit IgG (H1L) antibody (A-11034, Invitrogen)) were used. Cisplatin sensitivity and PARP inhibitor sensitivity of cells were determined either by crystal violet or XTT (39-1-phenylaminocarbonyl-3,4-tetrazolium-bis(4-methoxy-6-nitrobenzenesulfonic acid)) assays. A PARP inhibitor, AG14361, was a gift of Pfizer. Expression of targeted genes was knocked down by transient transfection of siRNA directed against FANCA (59-AAGGGTCAAGAGGGAAAAATA-39), BRCA2 (59-AACAACAATTACGAAC-CAAAC-39) and negative control (59-AATTCTCCGAACGTGTCACGT-39). Homologous recombination assay was done as previously described 22 . A BAC clone, RP11-37E23, was used as a probe for FISH on metaphase chromosome preparations of Capan-1 cells. Three DNA samples from patients with ovarian cancer with the BRCA2 mutation were obtained from Cedars-Sinai Medical Center through the Pacific Ovarian Cancer Research Consortium, and two from the tissue bank of the University of Washington. The study was approved by institutional review boards of the Fred Hutchinson Cancer Research Center and the University of Washington.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
